Immunoprecise Antibodies Valuation
| IPA Stock | USD 0.35 0.02 6.06% |
Immunoprecise Antibodies seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of Immunoprecise Antibodies from evaluating the firm fundamentals such as Return On Asset of -0.14, return on equity of -0.66, and Current Valuation of 24.55 M as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Immunoprecise Antibodies' price fluctuation is extremely dangerous at this time. Calculation of the real value of Immunoprecise Antibodies is based on 3 months time horizon. Increasing Immunoprecise Antibodies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immunoprecise Antibodies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunoprecise Stock. However, Immunoprecise Antibodies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.35 | Real 1.51 | Hype 0.35 |
The real value of Immunoprecise Stock, also known as its intrinsic value, is the underlying worth of Immunoprecise Antibodies Company, which is reflected in its stock price. It is based on Immunoprecise Antibodies' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Immunoprecise Antibodies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Immunoprecise Antibodies helps investors to forecast how Immunoprecise stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunoprecise Antibodies more accurately as focusing exclusively on Immunoprecise Antibodies' fundamentals will not take into account other important factors: Immunoprecise Antibodies Total Value Analysis
Immunoprecise Antibodies is currently projected to have company total value of 24.55 M with market capitalization of 15.07 M, debt of 13.68 M, and cash on hands of 19.24 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Immunoprecise Antibodies fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.55 M | 15.07 M | 13.68 M | 19.24 M |
Immunoprecise Antibodies Investor Information
The company has price-to-book (P/B) ratio of 0.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunoprecise Antibodies recorded a loss per share of 0.75. The entity last dividend was issued on the 23rd of November 2020. The firm had 1:5 split on the 23rd of November 2020. Based on the key indicators related to Immunoprecise Antibodies' liquidity, profitability, solvency, and operating efficiency, Immunoprecise Antibodies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Immunoprecise Antibodies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immunoprecise Antibodies has an asset utilization ratio of 40.87 percent. This suggests that the Company is making $0.41 for each dollar of assets. An increasing asset utilization means that Immunoprecise Antibodies is more efficient with each dollar of assets it utilizes for everyday operations.Immunoprecise Antibodies Ownership Allocation
Immunoprecise Antibodies has a total of 45.77 Million outstanding shares. Immunoprecise Antibodies retains 5.26 (percent) of its outstanding shares held by insiders and 4.16 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Immunoprecise Antibodies Profitability Analysis
The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 12.1 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Immunoprecise Antibodies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Immunoprecise Antibodies and how it compares across the competition.
About Immunoprecise Antibodies Valuation
The stock valuation mechanism determines Immunoprecise Antibodies' current worth on a weekly basis. Our valuation model uses a comparative analysis of Immunoprecise Antibodies. We calculate exposure to Immunoprecise Antibodies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunoprecise Antibodies's related companies.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States.
Immunoprecise Antibodies Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 25.6 M |
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |